Structural insights of homotypic interaction domains in the ligand-receptor signal transduction of tumor necrosis factor (TNF)

키워드

참고문헌 (76)

1. Chowdhury I, "Current concepts in apoptosis: the physiological suicide program revisited", Cell Mol Biol Lett, 11, pp.506~525 (2006)
2. Rich T, "Apoptosis : the germs of death", Nat Cell Biol, 1, pp.e69~e71 (1999)
3. Ola MS, "Role of Bcl-2 family proteins, caspases in the regulation of apoptosis", Mol Cell Biochem, 351, pp.41~58 (2011)
4. Brown S, "Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment", Nature, 418, pp.200~203 (2002)
5. Brown S, "Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding, engulfment", Nature, 418, pp.200~203 (2002)
6. Wilson NS, "Death receptor signal transducers: nodes of coordination in immune signaling networks", Nat Immunol, 10, pp.348~355 (2009)
7. Zhang JY, "CDK4regulation by TNFR1, JNK is required for NF-B–mediated epidermal growth control", J Cell Biol, 168, pp.561~566 (2005)
8. Mosselmans R, "Endocytic pathway of recombinant murine tumor necrosis factor in L-929 cells", J Immunol, 141, pp.3096~3100 (1988)
9. Chinnaiyan AM, "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1, CD95", Science, 274, pp.990~992 (1996)
10. Berghe TV, "Regulated necrosis: the expanding network of non-apoptotic cell death pathways", Nat Rev Mol Cell Bio, 15, pp.135~147 (2014)
11. Muzio M, "FLICE, a novel FADD-homologous ICE", CED- 3–like protease, is recruited to the CD95 (Fas, Cell, pp.1996, 85[DOI]
12. Walczak H, "Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo", Nat Med, 5, pp.157~163 (1999)
13. Tartaglia LA, "A novel domain within the 55 kd TNF receptor signals cell death", Cell, 74, pp.845~853 (1993)
14. Nagata S, "Apoptosis by death factor", Cell, 88, pp.355~365 (1997)
15. Scaffidi C, "FLICE is predominantly expressed as two functionally active isoforms, caspase-8", a, caspase-8, J Biol Chem, pp.1997, 272[DOI]
16. Sakahira H, "Cleavage of CAD inhibitor in CAD activation, DNA degradation during apoptosis", Nature, 391, pp.96~99 (1998)
17. Muzio M, "An induced proximity model for caspase-8 activation", J Biol Chem, 273, pp.2926~2930 (1998)
18. Zhou P, "Solution structure of Apaf-1 CARD, its interaction with caspase-9 CARD: a structural basis for specific adaptor", caspase interaction, 1999, pp.96, 11265~11270
19. Srinivasula SM, "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization", Mol Cell, 1, pp.949~957 (1998)
20. Cain K, "Caspase activation involves the formation of the aposome, a large(~700 kDa)caspase-activating complex", J Biol Chem, 274, pp.22686~22692 (1999)
21. Ortells MO, "Evolutionary history of the ligand-gated ion-channel superfamily of receptors", Trends Neurosci, 18, pp.121~127 (1995)
22. Ashkenazi A, "Death receptors: signaling, modulation", Science, 281, pp.1305~1308 (1998)
23. Berglund H, "The three-dimensional solution structure, dynamic properties of the human FADD death domain", J Mol Biol, 302, pp.171~188 (2000)
24. Kersse K, "The death-fold superfamily of homotypic interaction motifs", Trends Biochem Sci, 36, pp.541~552 (2011)
25. Vaughn DE, "Crystal structure of Apaf-1 caspase recruitment domain:an α-helical Greek key fold for apoptotic signaling", J Mol Biol, 293, pp.439~447 (1999)
26. Liepinsh E, "The death-domain fold of the ASC PYRIN domain, presenting a basis for PYRIN", PYRIN recognition, 2003, pp.332, 1155~1163
27. Yang JK, "Crystal structure of MC159 reveals molecular mechanism of DISC assembly, FLIP inhibition", Mol Cell, 20, pp.939~949 (2005)
28. Park HH, "The death domain superfamily in intracellular signaling of apoptosis, inflammation", Annu Rev Immunol, 25, pp.561~ (2007)
29. Qin H, "Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1", Nature, 399, pp.549~557 (1999)
30. Humke EW, "ICEBERG : a novel inhibitor of interleukin-1β generation", Cell, 103, pp.99~111 (2000)
31. Srimathi T, "Monomer", dimer transition of the caspase-recruitment domain of human Nod1, 2008, pp.47, 1319~1325
32. Pinheiro AS, "Three-dimensional structure of the NLRP7 pyrin domain: insight into pyrin-pyrin-mediated effector domain signaling in innate immunity", J Biol Chem, 285, pp.27402~27410 (2010)
33. Eberstadt M, "NMR structure, mutagenesis of the FADD(Mort1)death-effector domain", Nature, 392, pp.941~945 (1998)
34. Garvey TL, "Binding of FADD, caspase-8 to molluscum contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function", J Virol, 76, pp.697~706 (2002)
35. Weber CH, "A docking model of key components of the DISC complex: death domain superfamily interactions redefined", FEBS Lett, 492, pp.171~176 (2001)
36. Bertin J, "Death effector domain-containing herpesvirus, poxvirus proteins inhibit both Fas-and TNFR1-induced apoptosis", Proc Natl Acad Sci U S A, 94, pp.1172~1176 (1997)
37. Tibbetts MD, "The death effector domain protein family: regulators of cellular homeostasis", Nature Immunol, 4, pp.404~409 (2003)
38. Huang B, "NMR structure, mutagenesis of the Fas(APO-1", CD95)death domain, 1996, pp.457, 1019~1022
39. Steward A, "Topology is the principal determinant in the folding of a complex all-alpha Greek key death domain from human FADD", J Mol Biol, 389, pp.425~437 (2009)
40. Scott FL, "The Fas–FADD death domain complex structure unravels signalling by receptor clustering", Nature, 457, pp.1019~1022 (2009)
41. Taylor RC, "Apoptosis : controlled demolition at the cellular level", Nat Rev Mol Cell Biol, 9, pp.231~241 (2008)
42. Strasser A, "The many roles of FAS receptor signaling in the immune system", Immunity, 30, pp.180~192 (2009)
43. Itoh N, "A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen", J Biol Chem, 268, pp.10932~10937 (1993)
44. Krammer PH, "Life, death in peripheral T cells", Nat Rev Immunol, 7, pp.532~542 (2007)
45. Öztürk S, "Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life, death decisions", Exp Cell Res, 318, pp.1324~1331 (2012)
46. Shen C, "Crystal structure of the death effector domains of caspase-8", Biochem Bioph Res Co, 463, pp.297~302 (2015)
47. Vickers CJ, "Selective detection of caspase-3 versus caspase-7 using activity-based probes with key unnatural amino acids", ACS Chem Biol, 8, pp.1558~1566 (2013)
48. Jong WY, "Mechanism of procaspase-8 activation by c-FLIPL", Proc Natl Acad Sci USA, 106, pp.8169~8174 (2009)
49. Schleich K, "Stoichiometry of the CD95 death-inducing signaling complex:experimental, modeling evidence for a death effector domain chain model", Mol Cell, 47, pp.306~319 (2012)
50. Dickens LS, "A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death", Mol Cell, 47, pp.291~305 (2012)
51. Schleich K, "Molecular architecture of the DED chains at the DISC:regulation of procaspase-8 activation by short DED proteins c-FLIP, procaspase-8 prodomain", Cell Death Differ, pp.e1~e16 (2015)
52. Hoffmann JC, "A new C-terminal cleavage product of procaspase-8, p30, defines an alternative pathway of procaspase-8 activation", Mol Cell Boil, 29, pp.4431~4440 (2009)
53. Golks A, "The role of CAP3 in CD95 signaling: new insights into the mechanism of procaspase-8 activation", Cell Death Differ, 13, pp.489~498 (2006)
54. Öztürk S, "Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life, death decisions", Exp Cell Res, 318, pp.1324~1331 (2012)
55. Fricker N, "Model-based dissection of CD95 signaling dynamics reveals both a pro-and antiapoptotic role of c-FLIPL", J Cell Biol, 190, pp.377~389 (2010)
56. Aggarwal BB, "Human lymphotoxin. Production by a lymphoblastoid cell line, purification, , initial characterization", J Biol Chem, 259, pp.686~691 (1984)
57. Aggarwal BB, "Human tumor necrosis factor. Production, purification, , characterization", J Biol Chem, 260, pp.2345~2354 (1985)
58. Locksley RM, "The TNF, TNF receptor superfamilies: integrating mammalian biology", Cell, 104, pp.487~501 (2001)
59. Croft M, "Co-stimulatory members of the TNFR family:keys to effective T-cell immunity?", Nat Rev Immunol, 3, pp.609~620 (2003)
60. Idriss HT, "TNFα, the TNF receptor superfamily: Structure‐function relationship (s)", Microsc Res Tech, 50, pp.184~195 (2000)
61. Wajant H, "Tumor necrosis factor signaling", Cell Death Differ, 10, pp.45~65 (2003)
62. Zhang G, "Tumor necrosis factor family ligand–receptor binding", Curr. Opinion Struct Biol, 14, pp.154~160 (2004)
63. Ea CK, "Activation of IKK by TNFα requires site-specific ubiquitination of RIP1, polyubiquitin binding by NEMO", Mol Cell, 22, pp.245~257 (2006)
64. Vanlangenakker N, "TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I, II members", Cell Death Dis, 2, pp.e230~ (2011)
65. Rahighi S, "Specific recognition of linear ubiquitin chains by NEMO is important for NF-B activation", Cell, 136, pp.1098~1109 (2009)
66. Li J, "The RIP1", RIP3necrosome forms a functional amyloid signaling complex required for programmed necrosis, 2012, pp.150, 339~350
67. Moulin M, "IAPs limit activation of RIP kinases by TNF receptor 1 during development", Embo J, 31, pp.1679~1691 (2012)
68. Park YH, "Death domain complex of the TNFR-1, TRADD, , RIP1 proteins for death-inducing signaling", Biochem Bioph Res Co, 443, pp.1155~1161 (2014)
69. Yamaoka S, "Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation", Cell, 93, pp.1231~1240 (1998)
70. Moquin D, "The molecular regulation of programmed necrotic cell injury", Trends Biochem Sci, 35, pp.434~441 (2010)
71. Zhang DW, "RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis", Science, 325, pp.332~336 (2009)
72. Hsu H, "TRADD–TRAF2, TRADD–FADD interactions define two distinct TNF receptor 1 signal transduction pathways", Cell, 84, pp.299~308 (1996)
73. Park YH, "Formation of the death domain complex between FADD, RIP1 proteins in vitro", BBA-Proteins. Proteom, 1834, pp.292~300 (2013)
74. Jang MS, "Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD", Oncogene, 30, pp.471~481 (2011)
75. Kelley SK, "Preclinical studies to predict the disposition of Apo2L", tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics,, safety, 2001, pp.299, 31~38
76. El-Deiry WS, "Insights into cancer therapeutic design based on p53, TRAIL receptor signaling", Cell death differ, 8, pp.1066~1075 (2001)

관련 논문AI추천